Related Experiment Video
Updated: Jul 5, 2026
08:37
Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice
Published on: April 21, 2015
Cytokines in inflammatory bowel disease
1Intestinal Disease Research Unit Departments of Medicine and Pharmacology University of Calgary Alberta Calgary Canada.
Mediators of Inflammation
|January 1, 1997
Summary
Cytokines play a key role in inflammatory bowel disease (IBD) pathogenesis. Targeting these cytokines offers a promising therapeutic strategy for Crohn's disease and ulcerative colitis.
Area of Science:
- Immunology
- Gastroenterology
- Molecular Biology
Background:
- Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, is linked to complex immune dysregulation.
- Cytokines, signaling proteins of the immune system, are increasingly recognized for their critical roles in IBD pathogenesis.
- Research over the past decade has significantly advanced our understanding of cytokine involvement in intestinal inflammation.
Purpose of the Study:
- To review the specific cytokines implicated in the pathogenesis of inflammatory bowel disease.
- To evaluate the evidence supporting and refuting the role of individual cytokines in intestinal inflammation.
- To examine the therapeutic potential of targeting cytokines for IBD treatment.
Main Methods:
- Literature review of experimental and clinical studies on cytokines in IBD.
- Analysis of data from cytokine 'knockout' mouse models of colitis.
- Examination of cytokine production alterations in human Crohn's disease and ulcerative colitis patients.
Main Results:
- Multiple cytokines have been identified as key players in the inflammatory processes underlying IBD.
- Cytokine knockout models demonstrate the causal link between specific cytokines and colitis development.
- Altered cytokine profiles are consistently observed in patients with Crohn's disease and ulcerative colitis.
Conclusions:
- Cytokines are central to the pathogenesis of inflammatory bowel disease.
- Modulating cytokine production or action represents a rational and promising therapeutic avenue for IBD.
- Further research into cytokine-targeted therapies holds significant potential for improving patient outcomes.
More Related Videos
Related Concept Videos
01:20Inflammatory Bowel Disease II: Ulcerative Colitis
Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
01:25Inflammatory Bowel Disease III: Crohn's Disease
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:30Inflammatory Bowel Disease II: Crohn's Disease
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by transmural...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:26Inflammatory Bowel Disease I: Introduction
Inflammatory bowel disease is a group of chronic disorders marked by recurrent inflammation of the gastrointestinal tract due to an abnormal immune response against gut microflora. This leads to tissue damage. The two main forms are Crohn’s disease and ulcerative colitis.Crohn’s DiseaseCrohn’s disease is a relapsing inflammatory disorder that can affect any part of the GI tract, from the mouth to the anus. It involves all layers of the bowel wall (transmural) and shows “skip lesions” in which...